ANK-700 is under clinical development by Anokion and currently in Phase I for Relapsing Remitting Multiple Sclerosis (RRMS).
ACT-10041239 is under clinical development by Idorsia Pharmaceutical and currently in Phase I for Multiple Sclerosis.
Analysis of Biogen's stock performance in 2024, focusing on sales struggles, financial health, and valuation. Read more here.
Ever-Growing USA on MSN1d
Hollywood Icon Teri Garr Passes Away at 79: Celebrating a Legacy of Laughter and AdvocacyTeri Garr, best known for her roles in Tootsie and Mr. Mom, has passed away at the age of 79. After a career spanning decades ...
Children and adolescents with multiple sclerosis (MS) have a range of symptoms, signs, and diagnoses within five years before ...
An investigational drug for multiple sclerosis from Io Therapeutics has restored leg mobility and myelin nerve coatings in ...
Most MS treatments don't increase the risk for miscarriage or major birth defects when used during pregnancy, an analysis ...
COVID-19 infection is not associated with immediate changes in multiple sclerosis symptom severity or disability.
A software engineer has completed his year-long challenge of doing 300 press-ups every day in memory of his mother who had ...
In new court filings, Karen Spencer accuses her ex-husband Charles Spencer of a “long-term” affair with Dr. Cat Jarman, his ...
The following is a summary of “Effects of COVID-19 Infection on Symptom Severity and Disability in Multiple Sclerosis,” ...
I’m experiencing things that some people who have had M.S. for about 10 to 15 years they have not experienced," said Letisha Malcolm, who just earned her second doctoral degree from Morgan State.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback